Release of the First Evaluation Data of LISA TRACKER Kits Used by 3 Hospital Centres for the Monitoring of Patients Affected by Auto-Immune Diseases and Treated With Anti-TNF[alpha]

Dec 20, 2010, 08:00 ET from Biomedical Diagnostics

PARIS, December 20, 2010 /PRNewswire/ -- Biomedical Diagnostics has released the first evaluation data for LISA TRACKER kits.This innovative tool allows the clinicians to identify, at various moments of the treatment, a possible resistance with the medicine and to optimize the patients' management over time.

Biomedical Diagnostics, company dedicated to the development and to the marketing of innovative in vitro Diagnosticproducts, is specialized in particular in the auto-immune diseases. This recognized expertise allowed Biomedical Diagnostics to provide LISA TRACKER kits, the first CE marked tests.These kits allow physicians to benefit from additional biological parameters, within a few hours and from a simple blood sample, thanks to concomitant dosages of:

    - Circulating TNF[alpha];

    - Prescribed anti-TNF[alpha];

    - Anti-drug antibodies (ADAb) responsible for neutralizing the drug when
    they are developed by the patient.

Associated with a regular clinical evaluation, this diagnostic test becomes a real theranostic tool allowing:

    - to better profile responders to treatment;

    - to optimize the treatment of patients affected by chronic
    auto-immune diseases and treated by anti-TNF[alpha];

    - and to improve the patients' management in the long term.

LISA TRACKER diagnostic tests are specific for each anti-TNF[alpha]

We count at present, in seven bigger industrial nations, 9,3 million persons affected by an articulardisease and 2,1 million persons affected by a digestive disease, mainly Crohn Disease.

Several treatments, among which monoclonal antibodies such as anti-TNF[alpha], are prescribed to reduce the symptoms of these severe and chronic auto-immune diseases.

Nevertheless a certain number of patients present, in the course of treatment, a resurgence of the symptoms which can lead to additional irreversible articular damages. This change of the therapeutic response can be linked to various causes. However it is recognized that patients can develop an immunization.

"The simultaneous consideration of 3 additional biological information, at various moments of the treatment, represents a significant improvement in the monitoring of patients affected by auto-immune diseases and treated by anti-TNF[alpha]. Thanks to this diagnostic tool, we hope to take part and to facilitate the necessary implementation of a personalized treatment for every patient," indicates Michel Finance, Chief Executive Officer of Biomedical Diagnostics.

Communication on the first experiences on the use of LISA TRACKER kits in hospital centres at the 23rd Congress of the French Society of Rheumatology on November 30th

The hospital centres of La Pitie Salpetriere, Bordeaux and Kremlin-Bicetre / Clamart implemented the dosages with LISA TRACKER kits and correlated the results to clinical data of some of their patients in Rheumatology.

Professor Xavier Mariette, Chief of the Rheumatology Department at the Kremlin-Bicetre Hospital, mentions the importance of the dosage of these medicines and in this particular case of anti-TNF[alpha], in the monitoring of patients treated by anti-TNF[alpha] in the long term.

    Press contacts

    ALIZE RP Actifin
    Caroline Carmagnol     Marie-Caroline Cardi
    +33-6-64-18-99-59      +33-1-56-88-11-13
    caroline@alizerp.com   mccardi@actifin.fr

SOURCE Biomedical Diagnostics